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The optimal follow-up (FU) strategy for patients treated for localised renal cell carcinoma 
(RCC) remains unclear. Using the RECUR database, we studied imaging intensity utilised in 
contemporary FU to evaluate its association with outcome after detection of disease 
recurrence. Consecutive patients with nonmetastatic RCC (n = 1612) treated with curative 
intent at 12 institutes across eight European countries between 2006 and 2011 were included. 
Recurrence occurred in 336 patients. Cross-sectional (computed tomography, magnetic 
resonance imaging) and conventional (chest X-ray, ultrasound) methods were used in 47% 
and 53%, respectively. More intensive FU imaging (more than twofold) than recommended 
by the European Association of Urology (EAU) was not associated with improved overall 
survival (OS) after recurrence. Overall, per patient treated for recurrence remaining alive with 
no evidence of disease, the number of FU images needed was 542, and 697 for high-risk 
patients. The study results suggest that use of more imaging during FU than that 
recommended in the 2017 EAU guidelines is unlikely to improve OS after recurrence. 
Prospective studies are needed to design optimal FU strategies for the future. 
Patient summary: After curative treatment for localised kidney cancer, follow-up is 
necessary to detect any recurrence. This study illustrates that increasing the imaging 
frequency during follow-up, even to double the number of follow-up imaging procedures 
recommended by the European Association of Urology guidelines, does not translate into 
improved survival for those with recurrence. 
 
 
The optimal follow-up (FU) strategy for patients treated for localised renal cell carcinoma 
(RCC) is undetermined. There are controversies regarding modalities and the frequency and 
timing of imaging. Recent systematic reviews of retrospective studies have concluded that 
consensus regarding the optimal surveillance is lacking [1,2]. Moreover, it remains unclear if 
early diagnosis of recurrence improves survival. 
The RECUR database is a European Association of Urology (EAU) RCC Guidelines Panel 
initiative. RECUR is a collaborative multicentre consortium with protocol-based data 
collection to investigate comparators for evidence-based FU recommendation for localised 
RCC. The RECUR protocol is available online [3]. In contrast to previously published FU 
studies, the focus of RECUR is on management and outcomes once a recurrence is detected, 
rather than from the time of initial treatment with curative intent. 
For the present study, RECUR data for 1889 patients with localised RCC from 12 centres (all 
with appropriate institutional approval) in eight European countries (Supplementary material) 
were analysed. Eligible patients underwent surgery with curative intent from January 2006 
(the start of the tyrosine kinase inhibitor era) to December 2011. After exclusions, the final 
study population consisted of 1612 patients. Median FU for patients who did not experience 
recurrence or die during FU was 63 mo (interquartile range 58–76). Patient characteristics are 
listed in Supplementary Table 1. 
The validated risk grouping system described by Leibovich [4] was used for clear cell RCC 
and the UCLA Integrated Staging System [5] was used for non–clear cell RCC. Overall 
survival (OS) after recurrence was defined as the time from recurrence until death from any 
cause or, for patients still alive, to the date of last FU. The total number of imaging 
procedures per patient was defined as all imaging performed during FU. This was used to 
calculate the number of imaging procedures needed to identify one patient with recurrent 
disease, one patient with recurrent disease receiving treatment with curative intent, and one 
patient with no evidence of disease (NED) following treatment of the recurrence. 
On the basis of the FU recommendations in the EAU guidelines [6], we calculated the 
number of images patients within the three risk groups should have undergone until 
recurrence or last FU. The image ratio (IR) was defined as the total number of imaging scans 
divided by recommended number of imaging scans (Supplementary material). Finally, the 
correlation between different IR levels and OS after recurrence was investigated. Calculations 
for image use, cross-sectional imaging, and images needed were based on the total study 
population (n = 1612), while the estimation of OS after recurrence was based on those 
patients who experienced recurrence and for whom an IR could be established (n = 293; 
Supplementary material). 
Of 17 333 FU imaging procedures performed, 8142 (47%) were cross-sectional (computed 
tomography [CT] or magnetic resonance imaging) and 9191 (53%) were conventional (chest 
X-ray or ultrasound). Cross-sectional imaging increased significantly during the study period 
(Supplementary Fig. 1). Overall, 52 imaging procedures were needed to identify one patient 
with recurrent disease. Of the 336 patients with recurrences, 92 were treated with curative 
intent, of whom 32 were alive with NED. The total number of FU imaging procedures needed 
to identify one patient with a recurrence suitable for treatment with curative intent was 188. 
Finally, for one patient who was alive with NED after treatment with curative intent of a 
recurrence, a total of 542 imaging procedures were required (Table 1). Figure 1 demonstrates 
similar OS after recurrence for patients with IR of d0.75, 0.76–1.99, and t2.0. For the high-
risk group, for which the EAU guidelines recommend 12 imaging procedures (6 CT of the 
abdomen and 6 CT of the thorax) during 5 yr of FU, we found no OS improvement between 
patients undergoing t24 imaging procedures and those with d8 imaging procedures (p = 
0.985). Similar nonsignificant differences were observed for the other risk groups (data not 
shown). 
Imaging in most FU protocols follows defined intervals, with the highest imaging frequency 
for patients with the highest risk scores. The rationale is that regular imaging has the potential 
to reveal recurrences early while they are limited and asymptomatic. However, for such 
imaging strategies, the disease has to behave in a predictable pattern in the majority of 
patients, with recurrences growing linearly and spreading to distant sites in a predictable 
fashion. As a higher frequency of imaging was not linked to a better oncological outcome, 
one might conclude that imaging should be further increased. However, the increase in 
imaging needed to enhance early detection is not likely to be cost-effective. Furthermore, the 
biology of RCC may still preclude cure from recurrences in a proportion of patients, 
regardless of local or systemic treatment options following detection of recurrent lesions, as 
suggested in the recent TRACERx Renal study by Turajlic et al [7]. Theoretically, more 
refined and frequent imaging has the potential to introduce a leadtime bias resulting in earlier 
detection and therapeutic management without changing the outcome. 
As the RECUR database is retrospective with its inherent limitations, interpretation requires 
caution. All centres used their own FU programs with differing intervals for the individual 
imaging approaches. Therefore, it was not possible to demonstrate to what extent each patient 
underwent imaging at the recommended time point. Furthermore, we have simplified the 
EAU recommendation by accepting conventional imaging as equivalent to cross-sectional 
imaging. We acknowledge that CT detects recurrence with higher resolution than 
ultrasound/chest X-ray [8], and that use of conventional imaging might dilute the results 
obtained. However, in another RECUR report, CT did not show superiority over conventional 
imaging methods with regard to outcome after detection of recurrences [9]. The fact that we 
have included all histological subtypes may be a further limitation. However, the major 
guideline authorities (EAU, American Urological Association, and National Comprehensive 
Cancer Network) use the same FU recommendation for all RCC subtypes. 
A further importance of rationalising FU imaging is cost-effectiveness, as resources are 
allocated to patients presumed to have been cured that could otherwise be used for diagnosis 
or treatment. The question of the present cost-effectiveness might be raised, as 542 imaging 
procedures were needed to identify one patient treated for recurrence and being alive with 
NED. 
The present study suggests that a more intensive imaging frequency during FU than that 
recommended in the 2017 EAU guidelines is unlikely to improve OS after recurrence. 
Prospective studies are needed to design optimal FU strategies that may be more 
individualized on the basis of patient and tumour characteristics. 
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Fig. 1 – Overall survival after recurrence for different image ratio (IR) levels, where IR 
is the total number of imaging scans divided by the estimated number of imaging scans 
for the given follow-up period according to European Association of Urology guidelines. 
There were no significant differences between the groups. 
 
Table 1 – Number of imaging procedures needed for detection of one patient undergoing 
TCI for recurrent RCC and for one patient alive with NED after TCI of their 
recurrence 




































         
Low risk 806 8986 65 138 29 310 17 529 
Intermediate risk 497 5560 108 51 34 164 11 505 
High risk 309 2787 163 17 29 96 4 697 
Total 1612  17333 336 52 92  188 32  542 
RCC = renal cell carcinoma; PRT = presumed radical treatment; FU = follow-up; INI1P = 
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